Neo Ivy Capital Management Has $1.18 Million Stock Holdings in Stryker Corporation $SYK

Neo Ivy Capital Management lifted its holdings in shares of Stryker Corporation (NYSE:SYK) by 229.3% in the third quarter, according to its most recent filing with the SEC. The firm owned 3,188 shares of the medical technology company’s stock after acquiring an additional 2,220 shares during the period. Neo Ivy Capital Management’s holdings in Stryker were worth $1,179,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC lifted its stake in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares during the period. Schnieders Capital Management LLC. bought a new stake in shares of Stryker in the 2nd quarter valued at approximately $205,000. Malaga Cove Capital LLC acquired a new position in shares of Stryker in the 2nd quarter worth approximately $231,000. Bryn Mawr Trust Advisors LLC raised its holdings in shares of Stryker by 8.7% in the 2nd quarter. Bryn Mawr Trust Advisors LLC now owns 3,438 shares of the medical technology company’s stock worth $1,360,000 after buying an additional 275 shares in the last quarter. Finally, Vestmark Advisory Solutions Inc. lifted its position in shares of Stryker by 73.4% during the 2nd quarter. Vestmark Advisory Solutions Inc. now owns 7,463 shares of the medical technology company’s stock worth $2,953,000 after buying an additional 3,159 shares during the period. Institutional investors own 77.09% of the company’s stock.

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 5.90% of the company’s stock.

Stryker Price Performance

Stryker stock opened at $364.11 on Friday. The business’s fifty day moving average is $365.45 and its two-hundred day moving average is $369.00. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The firm has a market cap of $139.34 billion, a P/E ratio of 43.35, a P/E/G ratio of 2.13 and a beta of 0.85. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $404.87.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. The company had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period last year, the company posted $4.01 earnings per share. Equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker’s payout ratio is currently 41.90%.

Analyst Ratings Changes

A number of brokerages have weighed in on SYK. The Goldman Sachs Group set a $399.00 price target on Stryker in a research report on Friday, January 9th. Truist Financial cut their price objective on Stryker from $400.00 to $392.00 and set a “hold” rating for the company in a report on Thursday, December 18th. Wells Fargo & Company upped their target price on shares of Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. Raymond James Financial upgraded shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 target price for the company in a research report on Tuesday, January 6th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $435.00 price target on shares of Stryker in a report on Friday, November 14th. Fourteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $428.61.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.